

EQA round: KD4/23 - Glycated Haemoglobin

Deadline: 3.11.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(220) Haemoglobin A _{1c}	[mmol/mol]				169							169	167	99	
Sample A		44,6	1,7	3,8	169		CVP	44,6	0,32	12%	39,2	50	169	167	99
(14) Bio-Rad		44,7	1,6	3,6	45	0							45		
(25) TOSOH		45,5	1,3	2,8	45	0							45		
(60) Roche		43,7	1,4	3,2	14	0							14		
(150) Arkray		44,5	1,4	3,2	52	0							52		
Other					13	0							13		
								1x 1, 3x 34, 3x 46, 3x 58, 1x 162, 1x 177, 1x 999							
Sample B		60,3	2	3,3	169		CVP	60,3	0,38	12%	53	67,6	169	167	99
(14) Bio-Rad		60,1	2	3,4	45	0							45		
(25) TOSOH		60,9	1,8	3	45	0							45		
(60) Roche		60,7	2,1	3,5	14	0							14		
(150) Arkray		60,6	1,7	2,8	52	0							52		
Other					13	0							13		
								1x 1, 3x 34, 3x 46, 3x 58, 1x 162, 1x 177, 1x 999							